ZYME 241220 22.50C (ZYME241220C22500) Stock Options, News & Quotes

US OptionsDetailed Quotes

ZYME241220C22500

Watchlist

0.38
0.000.00%

15min DelayClose Nov 11 15:57 ET

0.00High0.00Low

Intraday

5D
Daily

News

Express News | HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $12 Price Target
BenzingaNov 22 06:54 ET
Zymeworks Hold Rating: Balancing FDA Milestones With Market Valuation and Future Risks
TipRanksNov 22 06:25 ET · Ratings
Leerink Partners Maintains Zymeworks(ZYME.US) With Buy Rating, Raises Target Price to $26
Moomoo NewsNov 21 16:31 ET · Ratings
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
WSJNov 21 09:30 ET
Sector Update: Health Care Stocks Rise Pre-Bell Thursday
MT NewswiresNov 21 09:13 ET
Express News | Zymeworks Inc : Leerink Partners Raises Target Price to $26 From $25
ReutersNov 21 08:55 ET

Comments

Jaguar8

Jul 22 05:03

NEWS

$Zymeworks (ZYME.US)$
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Zymeworks Inc. (Nasdaq: ZYME) announced FDA clearance of its Investigational New Drug (IND) application for ZW191, a novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor antibody-drug conjugate (ADC). ZW191 targets FR⍺-expressing tumors, including ovarian, gynecological cancers, and non-small...

Jaguar8

Jun 17 06:42

NEWS

$Zymeworks (ZYME.US)$
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
Zymeworks (Nasdaq: ZYME) announced that the FDA has cleared its investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody designed to treat mesothelin (MSLN)-expressing cancers such as ovarian cancer, non-small cell lung cancer, and mesothelioma. ZW171 aims to i...